

# NB-598

Catalog No: tcsc1274



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

131060-14-5

**Formula:**

$C_{27}H_{31}NOS_2$

**Pathway:**

Others

**Target:**

Others

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**


449.67

## Product Description

NB-598 is a potent and competitive inhibitor of **squalene epoxidase (SE)**, and suppresses triglyceride biosynthesis through the farnesol pathway.

IC50 & Target: squalene epoxidase

***In Vitro:*** NB598 (10  $\mu$ M) causes a  $36 \pm 7\%$  reduction in total cholesterol level of MIN6 cells. NB598 causes a significant decrease in cholesterol by  $49 \pm 2\%$ ,  $46 \pm 7\%$ , and  $48 \pm 2\%$  from PM, ER, and SG, respectively. NB598 dose-dependently inhibits insulin secretion under both basal (1 mM glucose) and glucose-stimulated (16.7 mM glucose) conditions. NB598 at concentrations up to 10  $\mu$ M does not affect peak outward KV currents or the voltage dependence of activation but increases current inactivation<sup>[1]</sup>. NB-598 (10  $\mu$ M) inhibits the synthesis of sterol and sterol ester from [<sup>14</sup>C]acetate without affecting the synthesis of other lipids such as phospholipids (PL), free fatty acids (FFA) and triacylglycerol (TG). In the absence of exogenous liposomal cholesterol, NB-598 reduces ACAT activity by 31%. NB-598 reduces ACAT activity by 22% even in the presence of a 600 PM concentration of liposomal cholesterol<sup>[2]</sup>. NB-598 suppresses the secretion of cholesterol and triacylglycerol from HepG2 cells into the medium<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!